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Underdiagnosis of fatal spotted fever may be attributed 
to nonspeciﬁ  c clinical features and insensitive acute-phase 
serologic studies. We describe the importance of molecu-
lar and immunohistochemical methods in establishing the 
postmortem diagnosis of locally acquired Israeli spotted fe-
ver due to Rickettsia conorii subsp. israelensis in a traveler 
returning to Israel from India. 
R
ickettsia conorii subspecies israelensis, the cause of Is-
raeli spotted fever (ISF), has been described in Israel, 
Italy, and Portugal. ISF is characterized by fever, headache, 
and rash after a tick bite (1,2). Since nonspeciﬁ  c clinical 
symptoms occur during disease onset, and no eschar is 
present in most Israeli cases, ISF, like other rickettsioses, 
may be misdiagnosed. Fatal outcome has been described in 
previously healthy children and adults, particularly when 
appropriate and timely antimicrobial drug treatment was 
not administered (2).
Serologic tests are the most widely available diagnos-
tic tools for spotted fever, but they are less than optimal for 
the diagnosis of rickettsial diseases in the acute phases (3). 
Autopsy ﬁ  ndings may be nondiagnostic unless specialized 
molecular and immunohistochemical techniques or cell 
culture-based methods are used to detect rickettsiae (3–5). 
We report a conﬁ  rmed case of fatal spotted fever in Israel 
due to R. conorii subsp. israelensis. 
The Case
A 51-year-old previously healthy Israeli man was ad-
mitted to Assaf Harofeh Medical Center in Israel for fe-
brile illness 1 month after he had returned from a trip to 
India. The patient lived in an urban environment in Israel 
and owned a dog. He had made two 1-month long business 
trips to India in March and in August 2005. He had been 
vaccinated against hepatitis A and typhoid fever, but had 
not taken antimalarial prophylaxis.
The patient’s symptoms started on September 23, 
2005, with fever ≈39°C accompanied by headache, weak-
ness, and frequent urination. After he was given cefu-
roxime sodium, a generalized rash developed. He was 
then referred to the hospital on September 26. On admis-
sion, he was febrile (38.9°C), and a physical examination 
showed diffuse macular rash on the trunk, extremities, the 
palms of his hands, and the soles of his feet. An allergy 
to cephalosporins was suspected and cefuroxime was dis-
continued. Results of the following studies were nondiag-
nostic: routine blood and urine cultures; blood smears for 
malaria parasites; and serologic tests for HIV, hepatitis A, 
B, and C, West Nile virus, dengue virus, Leptospira spp., 
cytomegalovirus, and Epstein-Barr virus. The patient’s 
condition worsened; on day 4 of hospitalization, severe 
muscle pain, tachycardia (189/min), tachypnea (40/min), 
oliguria, and generalized convulsions had developed. In-
travenous piperacillin-tazobactam (4.5 g 3 times a day) 
plus oral doxycycline (100 mg twice a day) were initiated. 
Later that day the patient experienced respiratory failure 
and was transferred to the intensive care unit. During the 
days that followed, the patient was in a deep coma with 
decerebrate posture and multiorgan system failure. The 
skin rash became overtly petechial, with areas compat-
ible with purpura fulminans. Because intravenous doxy-
cycline is not available in Israel, doxycycline tablets were 
administered through the nasogastric tube, combined with 
intravenous meropenem. The patient died on October 2, 
2005, on day 11 of illness (day 8 of hospitalization, day 5 
of doxycycline therapy). An autopsy was performed and 
serum samples and tissue from various organs were pre-
served at –70°C for further study.
At autopsy, jaundice and edema with diffuse hemor-
rhagic rash, including the conjunctivae, were evident. In-
ternal organs were congested, and moderate amounts of 
pleural ﬂ  uid and ascites were noted. A pressure mark was 
evident on the left cerebellar tonsil, which indicated in-
creased intracranial pressure. The cerebral cortex showed 
perivascular hemorrhages. Inﬂ  ammatory cell inﬁ  ltrates and 
occasional thrombi in the alveolar capillaries and arterioles 
were present in the lungs. Results of staining with silver-
methenamine and periodic acid-Schiff were negative for 
pathogens.
Immunohistochemical staining performed at the Cen-
ters for Disease Control and Prevention (Atlanta, GA, USA) 
(3) showed spotted fever group rickettsiae in the vascular 
endothelial cells of the patient’s brain and kidney (Figure 
1). Serologic tests for R. conorii from day 7 of illness yield-
ed negative results (both immunoglobulin [Ig] M and IgG). 
On day 11 of illness, IgG results remained negative and 
IgM results were borderline positive (Table). 
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Atlanta, Georgia, USAResults of nested PCR tests for spotted fever group 
rickettsiae (SFGR), performed at the Israeli National Ref-
erence Laboratory for Rickettsial Diseases on DNA sam-
ples prepared from serum collected on day 7 of illness (8), 
were negative. These tests were also applied to autopsy tis-
sue samples (liver, muscle, skin, lung, kidney) and yielded 
a 214-bp amplicon from the 17-kDa protein gene of the 
SFGR (Figure 2). BfaI restriction proﬁ  le of 17-kDa pro-
tein gene amplicons consisted of 2 fragments, 50 and 164 
bp that were identical to that of R. conorii subsp. conorii 
and R. conorii subsp. israelensis (8). A 208-bp fragment 
of the conserved 17-kDa Rickettsia spp. antigen gene was 
ampliﬁ  ed at CDC from a DNA specimen obtained from a 
serum sample collected during the autopsy, and indicated 
SFGR DNA in the patient’s bloodstream. An outer mem-
brane protein A (ompA) gene fragment (70–602 nt) was 
ampliﬁ  ed from the positive serum sample extracted at CDC 
and from skin, liver, and muscle samples extracted at the 
Israel Institute for Biological Research as described (9). 
Nucleotide sequences of each of the 4 ompA amplicons 
(GenBank accession no. EU122392) and R. conorii subsp. 
israelensis (U43797) were identical.
Conclusions
This case underscores the difﬁ  culties involved in es-
tablishing the diagnosis of ISF during the acute phase of 
the illness. It also emphasizes the importance of consider-
ing that returning travelers may have acquired the illness 
locally. Although rickettsial infections can be acquired by 
travelers to India (10), the long incubation time (1 month) 
and the positive diagnosis of the etiologic agent as R. 
conorii subsp. israelensis makes this possibility unlikely. 
An endemic ISF case due to dog ownership is the more 
likely scenario. On the other hand, physicians caring for 
travelers returning from Mediterranean countries such as 
Italy, Portugal, and Israel should be alert to the possibility 
of ISF in febrile patients. Absence of eschar in ISF may 
be an obstacle to the correct diagnosis as exempliﬁ  ed by a 
recent case of a UK traveler to Portugal (11).
Israeli spotted fever is endemic in Israel (2). National 
surveillance data have been available only since the early 
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Figure 1. A small vessel in the kidney (A) and a capillary in the 
cerbral cortex (B) positive with immunohistochemical stain speciﬁ  c 
for spotted fever group rickettsiae. Original magniﬁ  cation ×158.
Table. Diagnostic tests performed to identify spotted fever in the patient* 









IFA Serum IgM = 64, IgG<32  CDC‡
PCR Serum sediment 
Liver, muscle, skin, lung, kidney 
Liver, muscle, skin 
Rickettsia conorii subsp. israelensis
Spotted fever group rickettsiae 




IHC stain#  Brain, kidney  Positive CDC
11 (autopsy) 
Cell culture**  Liver, lung  Negative IIBR
*IFA, immunofluorescent assay; Ig, immunoglobulin; IIBR, Institute for Biological Research; CDC, Centers for Disease Control and Prevention; IHC, 
immunohistochemical. 
†IFA performed (6). Cutoff values for IgM and IgG are 100. 
‡IFA performed (7). Cutoff values for IgM and IgG are 64. 
§Nested PCR for 17-kDa protein gene (8). 
¶Nested and semi-nested PCR for 17 kDa protein gene and recombinant outer membrane protein A gene fragment, respectively, followed by sequencing (9).
#Three-micron sections cut from formalin-fixed, paraffin-embedded brain and kidney tissue samples were stained by using an immunoalkaline 
phosphatase technique with a hyperimmune rabbit anti–Rickettsia rickettsii antibody at a dilution of <500 (3).
**Homogenized samples from lung and liver were applied by centrifugation onto monolayer of Vero cells culture in 24-well plates and incubated for 2 
weeks at 35°C in 5% CO2 atmosphere incubator. Fatal Rickettsia conorii subsp. israelensis, Israel 
1970s (10). The incidence ranged from 0.7 to 10.3/100,000 
(20–370 annual cases) from 1971 through 1980; it has de-
clined steadily since 1980, reaching a nadir of 0.29/100,000 
(20 cases) in 2004. The highest annual incidence reported 
was among children <10 years of age (10.5/100,000), and 
the lowest among persons >65 years (2/100,000) (12). A 
strong seasonal pattern exists, with the highest incidence 
occurring between June and October (12).  
The case-fatality rate in Israel from 1971 through 1998 
ranged from 0% to 3.5%, with an average rate of 0.7% (12). 
This rate may be an underestimate because seronegative fa-
tal cases may not have been routinely investigated. Several 
examples of postmortem diagnoses in seronegative patients 
have been reported. In 1993, Yagupsky and Wolach de-
scribed 2 children, whose postmortem diagnosis of ISF was 
established by using cell culture methods and animal inoc-
ulation studies (5). In 1997, 2 cases of unexplained deaths 
in young adults (31 and 38 years of age) were diagnosed 
after immunohistochemical detection of rickettsial antigen 
in parafﬁ  n-embedded tissue obtained at autopsy (4,12). Fi-
nally, nested PCR applied to sera and tissue in several se-
rologically unconﬁ  rmed fatal cases of R. conorii infections 
was shown to be effective in establishing the correct di-
agnosis (8,13,14). PCR performed on whole blood or skin 
biopsy specimens of rash collected before treatment offers 
the possibility of improved early and rapid laboratory diag-
nosis of ISF and other rickettsial infections (8,14,15).
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